comparemela.com

Latest Breaking News On - Monument therapeutics - Page 1 : comparemela.com

Cambridge Cognition spin-out Monument Therapeutics accesses £1 5m for schizophrenia clinical development

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development  Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a p.

Neuroscience R&D Conference 2023: Unfolding the Recent Advancements in Preclinical and Translational Approaches Treating Neurodegenerative Disorders (London, United Kingdom - October 9-10, 2023) - ResearchAndMarkets com

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.